SLC5A2 and chronic kidney disease: The SGLT‐2 inhibitors increased from below 10% in 2019 to 25.06%, 17.3%, 42.4%, and 24.1% for ASCVD, high ASCVD risk, HF, and CKD patients, respectively, in 2022 (Figure 3).